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Abstract
Background: There is a need for biomarkers to better characterise individuals with COPD and to aid with the
development of therapeutic interventions. A panel of putative blood biomarkers was assessed in a subgroup of the
Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) cohort.
Methods: Thirty-four blood biomarkers were assessed in 201 subjects with COPD, 37 ex-smoker controls with
normal lung function and 37 healthy non-smokers selected from the ECLIPSE cohort. Biomarker repeatability was
assessed using baseline and 3-month samples. Intergroup comparisons were made using analysis of variance,
repeatability was assessed through Bland-Altman plots, and correlations between biomarkers and clinical
characteristics were assessed using Spearman correlation coefficients.
Results: Fifteen biomarkers were significantly different in individuals with COPD when compared to former
or non-smoker controls. Some biomarkers, including tumor necrosis factor-a and interferon-g,w e r e
measurable in only a minority of subjects whilst others such as C-reactive protein showed wide variability
over the 3-month replication period. Fibrinogen was the most repeatable biomarker and exhibited a weak
correlation with 6-minute walk distance, exacerbation rate, BODE index and MRC dyspnoea score in COPD
subjects. 33% (66/201) of the COPD subjects reported at least 1 exacerbation over the 3 month study with
18% (36/201) reporting the exacerbation within 30 days of the 3-month visit. CRP, fibrinogen interleukin-6
and surfactant protein-D were significantly elevated in those COPD subjects with exacerbations within 30
days of the 3-month visit compared with those individuals that did not exacerbate or whose exacerbations
had resolved.
Conclusions: Only a few of the biomarkers assessed may be useful in diagnosis or management of COPD where
the diagnosis is based on airflow obstruction (GOLD). Further analysis of more promising biomarkers may reveal
utility in subsets of patients. Fibrinogen in particular has emerged as a potentially useful biomarker from this cohort
and requires further investigation.
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Chronic obstructive pulmonary disease (COPD) is a
major cause of global morbidity and mortality and is
predicted to become the third leading cause of death by
2020 [1]. It is a multicomponent condition involving
both local and systemic pathological processes that
include airway obstruction, emphysema, mucus hyperse-
cretion, loss of lean body mass and an increased risk of
cardiovascular disease [2]. The most widely used marker
of disease severity and progression is the forced expira-
tory volume in one second (FEV1). However FEV1 corre-
lates poorly with both symptoms and other measures of
disease progression [3]. Moreover it does not differenti-
ate between the causes of airflow obstruction (i.e. small
airways disease or emphysema) or identify the extra-pul-
monary manifestations of COPD. There is clearly a need
for biomarkers that can aid with the diagnosis, risk stra-
tification and the assessment of therapeutic interven-
tions. The search for biomarkers has centred around
proteins and other molecules in exhaled breath conden-
sate, sputum, urine, bronchoalveolar lavage and blood
that have been implicated in the pathogenesis of COPD
[4]. Profiling of blood biomarkers has identified a num-
ber of biomarkers that may distinguish individuals with
COPD from control subjects [5]. However, additional
research is needed to determine the value of biomarkers
in characterizing COPD patients, following disease pro-
gression, and/or the ability to serve as intermediate or
surrogate endpoints in clinical studies.
We have used the ECLIPSE (Evaluation of COPD
Longitudinally to Identify Surrogate Endpoints) cohort
to evaluate a number of previously reported biomarkers,
and to identify new biomarkers for COPD [6]. This
cohort has already been used to evaluate serum CC-16,
surfactant protein D (SP-D) and CCL-18/PARC. SP-D
and CCL-18/PARC were elevated and CC-16 was
decreased in individuals with COPD when compared to
control subjects [7-9]. We report here the assessment of
a panel of 34 biomarkers in a subgroup of individuals
from the ECLIPSE cohort. The biomarkers were selected
based on previous work suggesting their potential asso-
ciation with the pathogenesis of COPD [5,10].
Methods
A sub-group of individuals was selected from the
ECLIPSE study (SCO104960, Clinicaltrials.gov identifier
NCT00292552) as the “biomarker cohort” in order to
evaluate 34 potential blood biomarkers in COPD [7,8].
The aims and operational aspects of ECLIPSE have been
described elsewhere [6]. Briefly ECLIPSE is a 3-year
multicentre, longitudinal, prospective study to identify
novel endpoints in COPD. Individuals aged 40-75 years
were recruited to the study if they had a smoking
history of ≥ 10 pack-years, a post bronchodilator ratio
between forced expiratory volume in 1 second (FEV1)
and forced vital capacity (FVC) ≤ 0.7 and Global Initia-
tive on Obstructive Lung Disease (GOLD) stage II
(FEV1 50-80% predicted), III (FEV1 30-50% predicted) or
IV (FEV1 < 30% predicted) COPD. Smoking (≥ 10 pack-
years) and non-smoking (< 1 pack-year) control subjects
were enrolled if they were aged 40-75 years and had
normal lung function (post bronchodilator FEV1 >8 5 %
predicted and FEV1/FVC ratio > 0.7). The “biomarker
cohort” consisted of 275 subjects (201 COPD subjects
with GOLD stage II-IV disease, 37 ex-smoker controls
and 37 non-smoker controls) matched to the full
ECLIPSE cohort. Only former smokers were included to
avoid the influence of acute cigarette smoke exposure
that might increase variability in our relatively small
sample size.
The methods used to evaluate lung function and the
extent of emphysema have been described previously
[8]. The number of exacerbations was assessed by tele-
phone contact on a monthly basis enquiring about
details of contact with doctors or hospital and the need
to take medications for exacerbations (oral steroids and/
or antibiotics) [11]. Exercise capacity was measured at
enrolment with a standard supervised six-minute walk
test. Assessments of depression, fatigue and level of dys-
pnoea were assessed with the CES-D (centre of epide-
miological studies depression scale) [12], FACIT
(functional assessment of chronic illness therapy) [13]
and modified MRC (Medical Research Council) [14]
dyspnoea scores, respectively.
Measurement of blood biomarkers
Whole blood was collected into vacutainer tubes at the
timepoints specified. For serum preparation, the blood
was allowed to clot for 30 minutes and serum was
obtained by centrifugation at 1500 g for 10-15 minutes.
For plasma preparation, whole blood was collected into
vacutainer tubes containing EDTA. Plasma was obtained
by centrifugation at 2000 g for 10-15 minutes. Serum
and plasma samples were stored at -80°C until analysed.
With the exception of fibrinogen and adiponectin, all
biomarkers were measured using validated immunoas-
says on the SearchLight Protein Array Platform (Aushon
Biosystems, Inc., Billerica, MA USA). Fibrinogen was
measured using an immunoturbidometric assay vali-
dated for use with EDTA plasma (K-ASSAY fibrinogen
test, Kamiya Biomedical Co., Seattle, WA, USA). Adipo-
nectin was measured using an individual ELISA method
(Linco Research, St. Charles, MO, USA). SP-D and CC-
16 concentrations were measured in serum as described
previously [7,8]. Assays were performed in duplicate to
allow assessment of assay variation (Additional File 1).
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ing biomarker levels at baseline and at 3 months. The
analysis included all subjects that had appropriate sam-
ples at the respective timepoints. In addition, 5 serum
biomarkers were assessed at as i n g l et i m e p o i n ta tt h e6
months study visit: adiponectin, b-defensin-2, CXCL7
(chemokine (C-X-C motif) ligand 7), leptin and MMP-8
(matrix metalloproteinase 8). Additional details of the
assay methods as well as assay performance information
are available in additional file 1.
Statistical Analysis
Variability of analytes was assessed through Bland-Alt-
man plots and frequency histograms. Due to non-nor-
mality of biomarker results as identified by Shapiro-
Wilk and Kolmogorov-Smirnov tests, all values in the
biomarker cohort were log-transformed prior to analysis.
All comparisons between groups were then conducted
by analysis of variance (ANOVA) based on the log-
transformed values with adjustment made for differences
in age and sex seen between the three groups. Spearman
correlation coefficients (based on ranks) were calculated
for correlations between biomarkers and clinical para-
meters. Analyte results that were below the limit of
quantification (LLOQ) were imputed as 1/2 times the
LLOQ. All analyses were performed with SAS
® Version
9.1 (SAS Institute, Cary, NC). Differences were consid-
ered significant if p ≤ 0.05. No adjustments were made
for multiple comparisons.
Ethics
The ECLIPSE study was conducted in accordance with
the Declaration of Helsinki and ICH Good Clinical Prac-
tice Guidelines. The study protocol was approved by the
local ethics committees for all 46 participating sites in 12
countries. All participants gave written informed consent.
Results
Assessment of biomarkers in COPD and control subjects
The characteristics of the cohort selected for the bio-
marker analysis are shown in Table 1. The cohort con-
sisted of 201 individuals (all former smokers) with
GOLD stage II-IV COPD, 37 smoker controls and 37
non-smoker controls. There were fewer males in the
Table 1 Baseline characteristics of the biomarker cohort
Characteristic COPD Subjects Smoker Controls Non-smoker Controls
Number 201 37 37
Age (yrs) 64.5 (6.0) 60.7 (7.6) 60.0 (8.8)
Male (%) 73% 68% 38%
Smoking, pack-years 45.7 (26.9) 29.3 (16.5) 0.0 (0.2)
FEV1 % predicted 43.8 (17.2) 109.6 (12.3) 115.9 (11.9)
% Low attenuation area on CT (< -950HU) 22.7 (13.7) 4.6 (4.5) 5.3 (5.5)
Radiologist Score < 5% emphysema 20% 95% 97%
5-25% emphysema 18% 5% 0
25-50% emphysema 15% 0 3%
> 50% emphysema 48% 0 0
% reversibility FEV1 9.6 (11.2) 3.7 (5.1) 2.2 (4.9)
BMI 26.9 (5.5) 29.2 (4.9) 27.1 (6.1)
Fat free mass index 17.1 (2.6) 18.2 (2.5) 16.8 (2.6)
Number of exacerbations in year prior to enrollment in ECLIPSE 0 46% 100% 97%
1 26% 0 3%
2 18% 0 0
3 or more 10% 0 0
6 min walk (m) 384 (124)
BODE Index 3.4 (2.2)
mMRC score 1.9 (1.1) 0.2 (0.5) 0.1 (0.4)
CES-D score 11.5 (9.0) 7.1 (8.8) 5.3 (5.1)
FACIT score 34.8 (10.6) 44.4 (8.4) 47.4 (4.3)
SGRQ-C Total score 52.9 (18.9) 8.4 (11.9) 2.5 (2.3)
BMI = Body Mass Index; BODE = BMI (B), airflow obstruction (O) as measured by the post-bronchodilator FEV1 (percentage of predicted value), dyspnoea (D)
assessed by the modified Medical Research Council (mMRC) score, and exercise tolerance (E) measured by 6-minute walking distance; FEV1 = Forced Expiratory
Volume in 1 second; SGRQ-C = St. Georges respiratory questionnaire for COPD patients. Values expressed as mean (standard deviation) or as percentage.
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trol groups were on average younger than COPD sub-
jects; multivariate analysis was used to adjust for age
and sex prior to comparison of data between groups.
Comparisons were made between potential biomarkers
in COPD subjects and both smoker and non-smoker
controls with normal lung function. At baseline, 15 ana-
lytes were significantly different between COPD subjects
and either smoker or non-smoker controls: adiponectin,
b-defensin-2, CRP (C-reactive protein), CCL18 (Chemo-
kine (C-C motif) ligand 18), fibrinogen, hepatocyte
growth factor, CXCL10, IL-12p40, IL-6, IL-8, MMP-8,
MMP-9, CCL2, myeloperoxidase and prolactin (Table
2). Significant differences between individuals with
COPD and both control groups were seen with b-defen-
sin-2, CRP, CCL18, fibrinogen and MMP-8.
There were no significant differences between cases and
controls for the other markers and therefore these were
not analysed further (Table 3). Importantly, the concentra-
tions of a number of analytes were above the lower limit
of quantification in only a small percentage of subjects:
TNF-a (10% COPD subjects, 10% combined controls),
interferon-g (6% COPD subjects, 6% combined controls),
IL-10 (14% COPD subjects, 12% combined controls), IL-
15 (17% COPD subjects, 15% combined controls), IL-17 (<
1% COPD subjects, 0% combined controls) and IL-1b
(21% COPD subjects, 22% combined controls).
Assessment of biomarkers at 3 months and the effect of
exacerbations
Over the 3 month period of this study, 33% (66/201) of
the COPD subjects reported at least one exacerbation as
defined by the requirement for antibiotics or oral corti-
costeroids or admission to hospital. Of these, 18% (36/
201) of the COPD subjects had exacerbations within 30
days of the 3-month study visit. In addition, 4 COPD
subjects were still taking an oral steroid within 2 weeks
of the 3-month visit and 1 subject was taking azithromy-
cin. CRP, fibrinogen, IL-6 and SP-D were significantly
higher in these subjects (Table 4 and Additional File 2).
Assessment of repeatability over 3 months
Twelve of the 15 biomarkers of interest were assessed
for repeatability between the baseline and 3-month
Table 2 Baseline values for biomarkers with a significant difference between COPD subjects and either smoking or
non-smoking controls.
COPD Subjects Smoker
Controls
Non-smoker
Controls
Biomarker N Median (IQR) N Median
(IQR)
COPD Subjects vs
Smoker Controls
N Median
(IQR)
COPD Subjects vs Non-
smoker Controls
Adiponectin (ng/mL)* 198 15614.5
(10340.0)
37 10856.0
(6145.0)
< 0.001 36 16124.5
(6428.5)
0.270
b-Defensin-2 (pg/mL)* 199 1222.3
(1794.8)
37 771.6 (784.2) 0.003 37 648.2 (964.1) 0.042
CCL2 (pg/mL) 201 615.0 (395.0) 37 530.0 (365.0) 0.065 37 460.0 (445.0) 0.017
CCL18 (pg/mL) 193 96000.0
(93000.0)
37 67000.0
(40000.0)
0.018 35 68000.0
(34000.0)
0.041
C-reactive protein (μg/mL) 200 5.38 (10.62) 37 3.13 (5.27) 0.036 35 2.17 (3.96) 0.002
CXCL10 (pg/mL) 198 79.7 (38.0) 37 67.8 (26.6) 0.085 35 65.8 (30.4) 0.017
Fibrinogen (mg/dL) 200 466.0 (117.5) 37 425.0 (100.0) 0.002 37 387.0 (83.0) < 0.001
Hepatocyte growth factor
(pg/mL)
199 589.2 (492.7) 37 475.3 (303.6) 0.324 37 421.7 (217.7) 0.012
Interleukin-6 (pg/mL) 194 0.2 (2.8) 37 0.2 (0.0) 0.004 37 0.2 (0.4) 0.072
Interleukin-8 (pg/mL) 190 8.8 (5.2) 36 7.7 (4.8) 0.051 34 6.7 (3.0) 0.009
Interleukin-12 p40 (pg/
mL)
177 1.6 (2.8) 32 2.3 (3.5) 0.343 32 0.6 (2.3) 0.017
Matrix metalloproteinase-8
(pg/mL)*
198 9005.8
(10853.0)
37 7393.7
(7231.2)
0.003 37 6607.9
(5241.8)
< 0.001
Matrix metalloproteinase-9
(pg/mL)
201 238020.0
(202960.0)
37 182700.0
(92460.0)
0.198 37 158180.0
(85815.0)
< 0.001
Myeloperoxidase (pg/mL) 198 34680.0
(34305.0)
36 24770.0
(19280.0)
0.195 37 20800.0
(17100.0)
0.043
Prolactin (pg/mL) 196 525.0 (462.5) 37 345.0 (260.0) < 0.001 36 580.0 (325.0) 0.771
Values are expressed as median (IQR), p values are based on log transformed results adjusted for age and sex. Biomarkers marked with * were measured at a
single timepoint.
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Page 4 of 10study visits. Results from subjects with either exacerba-
tions within 4 weeks or who had been taking oral ster-
oids within 2 weeks of the 3-month study visit were
excluded from this analysis. Figure 1 shows Bland Alt-
man plots and graphs of the distribution of percentage
variability for several of the biomarkers with the largest
differences between COPD and controls (see Additional
File 3 for the remaining biomarkers). Repeatability was
assessed by calculating the proportion of values at three
months that were within 25% of the baseline value
(Table 5). Twenty-five percent was chosen as this
reflects the typical total error associated with the types
Table 3 Baseline values for biomarkers in which there was no significant difference between COPD subjects and either
smoking or non-smoking controls.
COPD Subjects Smoker Controls Non-smoker
Controls
Biomarker N Median
(IQR)
N Median
(IQR)
COPD Subjects vs
Smoker Controls
N Median
(IQR)
COPD Subjects vs
Non-smoker Controls
Brain-derived neurotrophic
growth factor (pg/mL)
200 36640.0
(17870.0)
37 35140.0
(14420.0)
0.656 37 35620.0
(10060.0)
0.381
CCL4 (pg/mL) 201 109.8 (86.0) 37 117.2 (70.0) 0.846 37 89.6 (86.2) 0.183
CCL23 (pg/mL) 201 501.8 (217.0) 37 443.0 (210.6) 0.483 37 468.0 (200.4) 0.178
CCL24 (pg/mL) 193 93.5 (124.0) 36 74.5 (100.0) 0.294 35 60.0 (61.5) 0.089
CXCL5 (pg/mL) 201 1415.0
(1065.0)
37 1265.0 (500.0) 0.144 37 1425.0 (975.0) 0.817
CXCL7 (pg/mL)* 199 34270367
(21359723)
37 36867340
(17597022)
0.582 36 33070725
(16762456)
0.425
CXCL11 (pg/mL) 200 19.8 (15.4) 36 18.4 (17.3) 0.488 36 16.8 (13.3) 0.249
Interferon-g (pg/mL) 201 0.4 (0.0) 37 0.4 (0.0) 0.346 35 0.4 (0.0) 0.584
Interleukin-1b (pg/mL) 199 0.2 (0.0) 36 0.2 (0.2) 0.185 37 0.2 (0.0) 0.576
Interleukin-10 (pg/mL) 201 0.4 (0.0) 37 0.4 (0.0) 0.697 37 0.4 (0.0) 0.433
Interleukin-15 (pg/mL) 187 0.8 (0.0) 37 0.8 (0.0) 0.227 36 0.8 (0.0) 0.971
Interleukin-17 (pg/mL) 201 0.8 (0.0) 37 0.8 (0.0) 0.630 37 0.8 (0.0) 0.632
Interleukin-1 receptor antagonist
(pg/mL)
193 217.4 (269.9) 36 204.6 (127.6) 0.609 34 139.0 (130.0) 0.056
Leptin (pg/mL)* 199 12857.5
(21025.5)
37 10074.8
(16770.9)
0.622 37 13103.6
(26107.2)
0.058
Tissue inhibitor of
metalloproteinase-1 (pg/mL)
201 329500.0
(142100.0)
37 285800.0
(128900.0)
0.215 37 255100.0
(149400.0)
0.302
Transforming Growth Factor-a
(pg/mL)
197 3.9 (10.0) 36 3.7 (9.7) 0.674 36 1.2 (5.4) 0.056
Tumor necrosis factor receptor
type I (pg/mL)
201 1530.0 (655.0) 37 1525.0 (521.4) 0.999 37 1400.0 (600.0) 0.494
Tumor necrosis factor receptor
type II (pg/mL)
196 1065.0 (545.0) 37 920.0 (525.0) 0.454 36 915.0 (537.5) 0.930
Tumor necrosis factor-a (pg/mL) 201 2.4 (0.0) 36 2.4 (0.0) 0.178 37 2.4 (0.0) 0.667
Values expressed as median (IQR), p values based on log transformed results adjusted for age and sex. Biomarkers marked with * were measured at a single
timepoint.
Table 4 The effect of exacerbations on biomarkers.
Biomarker Exacerbation within 30 days No or Resolved Exacerbations p-value
N Median (IQR) N Median (IQR)
Fibrinogen (mg/dL) 33 534.0 (156.0) 157 464.0 (115.0) < 0.001
Interleukin-6 (pg/mL) 30 2.8 (6.0) 151 0.6 (2.6) < 0.001
Surfactant Protein D (ng/mL) 32 132.7 (135.9) 148 101.0 (70.7) 0.011
C-reactive protein (μg/mL) 33 6.96 (6.52) 153 3.98 (6.76) 0.048
Biomarker results at 3 months for COPD subjects with an exacerbation within 30 days of the study visit and COPD subjects with no exacerbations or resolved
exacerbations. Values are expressed as median (IQR), p values are based on log transformed results. The table shows those biomarkers that were significantly
different between the two groups. Results for the remaining biomarkers are included additional Table 2.
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Figure 1 Bland Altman plots and frequency histograms of differences between baseline and 3-month results illustrating variability of
selected biomarkers. All values have been log transformed prior to analysis.
Table 5 Variability of selected biomarkers in stable subjects.
Biomarker COPD Subjects* Smoker Controls Non-smoker Controls All Subjects
CC-16 132/146 (90%) 29/35 (83%) 31/34 (91%) 192/215 (89%)
C-reactive protein 32/153 (21%) 7/36 (19%) 12/35 (34%) 51/224 (23%)
CCL24 51/144 (35%) 8/32 (25%) 16/35 (46%) 75/211 (36%)
Fibrinogen 139/156 (89%) 31/36 (86%) 35/36 (97%) 205/228 (90%)
Hepatocyte growth factor 57/152 (38%) 17/36 (47%) 19/36 (53%) 93/224 (42%)
Interleukin-6 55/147 (37%) 22/34 (65%) 24/36 (67%) 101/217 (47%)
Interleukin-8 67/141 (48%) 12/35 (34%) 13/33 (39%) 92/209 (44%)
Interleukin 12p40 64/124 (52%) 14/27 (52%) 20/30 (67%) 98/181 (54%)
CXCL10 86/152 (57%) 19/35 (54%) 23/34 (68%) 128/221 (58%)
CCL2 72/154 (47%) 22/36 (61%) 13/36 (36%) 107/226 (47%)
Matrix metalloproteinase-9 53/154 (34%) 8/36 (22%) 18/36 (50%) 79/226 (35%)
CCL23 93/154 (60%) 20/36 (56%) 23/36 (64%) 136/226 (60%)
Myeloperoxidase 52/154 (34%) 7/35 (20%) 15/36 (42%) 74/225 (33%)
CCL-18 53/135 (39%) 15/26 (58%) 15/35 (43%) 83/196 (42%)
Prolactin 47/148 (32%) 7/36 (19%) 9/35 (26%) 63/219 (29%)
Surfactant Protein D 107/145 (74%) 26/35 (74%) 30/34 (88%) 163/214 (76%)
Expressed as a percentage of subjects in which the 3-month value was within 25% of the baseline value. *COPD subjects with exacerbations within 30 days of
the 3-month visit or subjects using oral steroids within 14 days of the 3 month visit were excluded.
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[15]. Fibrinogen was the least variable biomarker with 3-
month values that were within 25% of the baseline value
for 89% of the COPD subjects. CRP was the most vari-
able biomarker with only 21% of COPD subjects having
a 3-month value that was within 25% of the baseline
value. For most of the other analytes, the 3-month
values were within 25% of the baseline values for 40-
50% of the subjects. The same analysis was retrospec-
tively applied to the data from the biomarker cohort for
CC-16 and SP-D [7,8]. Ninety percent of CC-16 values
at 3-months were within 25% of baseline and 74% of 3-
month SP-D values were within 25% of baseline for the
COPD subjects.
Correlation of biomarkers with the severity of COPD and
the presence of emphysema
For the baseline assessments, six biomarkers showed
weak correlation with COPD disease severity as defined
by GOLD stage: b-defensin-2 (r = 0.2, p = 0.005), IL-8
(r = 0.15, p = 0.043), MMP-8 (r = 0.19, p = 0.007),
MMP-9 (r = 0.16, p = 0.024), adiponectin (r = 0.18, p =
0.009) and hepatocyte growth factor (r = -0.21, p =
0.003). MMP-8 (r = 0.15, p = 0.043), MMP-9 (r = 0.18,
p = 0.011) and adiponectin (r = 0.26, p =< 0.001) also
correlated weakly with the percentage of emphysema as
defined by low attenuation area on chest CT scans;
MMP-9 correlated with the radiologists’ score of
emphysema (r = 0.18, p = 0.010).
Fibrinogen as a promising biomarker for COPD
The most stable biomarker over 3 months in the
ECLIPSE biomarker cohort was fibrinogen. It was signif-
icantly elevated in COPD patients relative to both ex-
smoking and non-smoking controls although it was not
associated with the severity of COPD as assessed by
GOLD score or the severity of emphysema. There was a
weak association with the number of reported exacerba-
tions (0, 1, 2, 3+) in the year prior to the study, with a
Spearman correlation coefficient (r) of 0.21 (p = 0.003)
and fibrinogen was elevated in those subjects with unre-
solved exacerbations at 3 months compared with sub-
jects that did not exacerbate or whose exacerbations had
resolved. Decreased exercise tolerance as measured by
6-minute walk distance was also associated with higher
levels of plasma fibrinogen (r = -0.23, p = 0.001) and
there were associations with BODE index (r = 0.20, p =
0.007) and MRC dyspnoea score (r = 0.17, p = 0.021).
Discussion
A subgroup of the ECLIPSE cohort was used to assess
thirty-four putative blood biomarkers for their associa-
tions with important characteristics of COPD. The ana-
lytes that were chosen have previously been associated
with either local or systemic features of COPD [5,10]. In
subjects with stable COPD, fifteen analytes had signifi-
cantly different concentrations in the COPD cohort as
compared with smoker and non-smoker controls.
Twelve of these were assessed for repeatability; this
revealed wide variation over 3 months for many of the
analytes, particularly CRP. Similar variability in a num-
ber of the biomarkers assessed in the ECLIPSE cohort
has been shown by Man and colleagues in a cohort of
41 COPD subjects over a two week period [16] though
less variable results were reported when measured at a
yearly interval [17].
It is known that COPD is an inflammatory disease
[18] and indeed CRP, fibrinogen and IL-6, all considered
to be markers of systemic inflammation, are all signifi-
cantly raised in COPD subjects compared to control
subjects in this and in other studies [19-22]. They have
received much attention to determine their value as
potential COPD biomarkers [23]. In addition, CRP, fibri-
nogen, and IL-6 have been reported to be elevated dur-
ing exacerbations of COPD [24-28]. Increased CRP and
fibrinogen have also been associated with increased risk
for COPD hospitalizations [29-31]. In the ECLIPSE bio-
marker cohort, fibrinogen was elevated in COPD sub-
jects, demonstrated excellent repeatability over time in
stable disease and was associated with BODE index and
MRC dyspnoea score. Data from this cohort have not
confirmed a previously recorded correlation with GOLD
stage [32], but baseline fibrinogen associates with
exacerbation frequency in ECLIPSE and other cohorts
[11,33] and with exercise tolerance. Thus it may reflect
a more global assessment of disease severity and there-
fore be a useful biomarker in COPD. IL-6 and CRP are
both significantly raised in COPD and are yet further
raised during exacerbations; however they display wide
variability in stable subjects over three months and
therefore their value as useful biomarkers of COPD
would appear to be limited. Additionally, we found no
significant association between TNF-a and COPD
despite an association being described previously [34].
Importantly, circulating TNF-a was detectable in only
approximately 10% of the subjects in the ECLIPSE bio-
marker cohort. The finding of low circulating TNF-a
and the inability to detect it in many subjects in the cur-
rent study is similar to that reported for COPD subjects
included in a study of the effects of infliximab [35].
Further evaluation of serum TNF-a in the full ECLIPSE
cohort confirmed that it is not measurable in a large
percentage of subjects [36]. We also observed that
serum concentrations of SP-D were both reproducible
and elevated in COPD subjects with unresolved exacer-
bations compared with those with stable disease. This
finding is consistent with our earlier report associating
baseline serum concentrations of SP-D with
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the findings of others [37,38].
Many of the analytes studied that were different
between cases and controls may play important roles as
chemoattractants for monocytes/macrophages (IL-8, IL-
12p40, CCL2), lymphocytes (CCL18, CXCL10) and neu-
trophils (IL-8) in driving inflammation in individuals
with COPD. Unfortunately, many of the analytes we
assessed showed poor repeatability when measured at a
3-month interval and thus they may have limited utility
as markers of disease progression or measures of the
effects of drug intervention. It is however possible that
they may be useful to help define subgroups of COPD
subjects based on common underlying disease mechan-
isms [39]. Studies with larger numbers of subjects will
be required to determine if this is the case.
Aberrant tissue destruction and repair is known to be
central to the development of emphysema [10]. MMP-8
and MMP-9 are two proteases that are believed to play
an important role in the tissue destruction that results
in emphysema [40,41] and both are raised in COPD
subjects in the biomarker cohort. Consistent with other
studies [42,43], there was evidence that they correlated
with GOLD stage and amount of emphysema and so
may be useful in differentiating individuals with emphy-
sema from those with predominantly airway disease.
Hepatocyte growth factor plays a role in tissue regenera-
tion [44] and was shown in a small study to be
increased in bronchoalveolar lavage of COPD subjects
and smokers with normal lung function [45]. The
repeatability of MMP-8 remains untested; however the
wide variability of MMP-9 and hepatocyte growth factor
over 3 months suggests that they are unlikely to be use-
ful in clinical applications.
b-defensin-2 and myeloperoxidase play a role in pul-
monary immunity [46,47]. We provide supportive evi-
dence that circulating myeloperoxidase is raised in
COPD [48] and show that b-defensin-2 is also higher in
individuals with this disease. b-defensin-2 may also
reflect disease severity as defined by GOLD stage. How-
ever additional profiling is required before it can be con-
fidently deemed a useful biomarker in COPD.
Adiponectin and prolactin levels have been shown to
be altered in subjects with COPD [5,49], however the
mechanisms underlying this remain uncertain. Both
have wide ranging metabolic effects and possible roles
in the inflammatory response [50]. For both analytes,
significant differences were seen between COPD sub-
jects and only one of the control groups and marked
variability was seen in stable disease. Although highly
elevated in COPD subjects, the temporal variability asso-
ciated with serum myeloperoxidase may confound its
use in clinical trials. However, adiponectin, prolactin
and myeloperoxidase may have some utility in diagnos-
tic tests that combine a panel of inflammatory markers
to describe the underlying inflammatory process in
some COPD patients.
Our study has several limitations. In assessing putative
biomarkers for repeatability, measures were taken at
baseline and at 3 months which is the approximate
duration of many COPD Phase IIa intervention studies.
Though this interval is relatively short, it is conceivable
that during this time period there may have been signifi-
cant clinical changes, changes in pharmacological treat-
ment or as we observed in our cohort, intercurrent
exacerbations. Any of these could create a “true” change
in biomarker level and thus the assessment of repeat-
ability may overestimate how variable markers are over
time. For example, Hurst [24], reported that the concen-
trations of CCL18, adiponectin, CRP, and IL-6 are
increased during exacerbations. In order to better esti-
mate reproducibility during stable disease, results from
subjects with exacerbations that were not resolved at
least 30 days prior to the 3 month visit were excluded
from the repeatability analysis as were subjects who had
been taking oral steroids within 2 weeks of the 3 month
visit. The control populations in the ECLIPSE cohort
were chosen on the basis of smoking status and the
absence of COPD. Individuals may have co-morbidities
that are inflammatory in nature and therefore influence
the levels of biomarkers. However this is unlikely as
details of co-morbidities were obtained at recruitment
to the study. Though many of the biomarkers examined
showed statistically significant differences between
groups, no allowances were made for multiple compari-
sons in interpreting the statistical significance of the
results [51]. Additionally corrections had to be made for
differences in baseline characteristics between cases and
controls as this study was intended to be exploratory
with the primary intent of identifying biomarkers for
follow up in the full ECLIPSE cohort or other COPD
cohorts.
Conclusions
We have identified several potentially clinically relevant
blood biomarkers that are elevated in COPD subjects
when compared to controls. In particular, fibrinogen
appears to be the most repeatable over the three-month
period tested. Surfactant protein D and CC-16 have also
been shown to be repeatable [7,8]. These now need to
be more rigorously assessed to clarify their repeatability
in stable disease and studied in a longitudinal fashion to
ascertain whether they can be used as surrogates for dis-
ease phenotype, severity and/or progression. Interven-
tional studies will also be needed to qualify them for use
as intermediates in COPD drug development.
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Additional file 1: Additional Table 1. Biomarker Assay Performance
Information. Intra- and Inter-assay variability of biomarker assays.
Additional file 2: Additional Table 2. Biomarker results at 3 months for
COPD subjects with an exacerbation within 30 days of the study visit
and COPD subjects with no exacerbations or resolved exacerbations.
Results for the biomarkers not shown in Table 4 in the main manuscript.
Additional file 3: Additional Figure 1. Bland Altman plots and
frequency histograms of differences between baseline and 3-month
results illustrating biomarker variability. Results for the biomarkers not
shown in Figure 1 within the main manuscript.
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